DBV Technologies vs Korro Bio
Korro Bio reported revenue of $6 million in fiscal 2025, about the same as DBV Technologies' $6 million in fiscal 2025. DBV Technologies' revenue grew 35.8% in its latest year, and Korro Bio's grew 181.5%. DBV Technologies had an operating margin of -2609.2%, against -1906.4% at Korro Bio. Free cash flow was −$122 million at DBV Technologies and −$79 million at Korro Bio.
Side by side
| DBV Technologies | Korro Bio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6M | $6M |
| Revenue growth | 35.8% | 181.5% |
| Revenue growth a year, last 5 years | −13.1% | −29.6% |
| Gross margin | — | — |
| Operating margin | −2,609.2% | −1,906.4% |
| Net margin | −2,607.3% | −1,834.5% |
| Free cash flow | −$122M | −$79M |
| Free cash flow margin | −2,159.6% | −1,237.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 43.9% | 5.3% |
| Last close | $9.42 | $12.19 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $15.5 million | bought $2.4 million, sold $5.7 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
DBV TechnologiesKorro Bio
Operating margin
Percent of revenue
DBV TechnologiesKorro Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
DBV TechnologiesKorro Bio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the DBV Technologies and Korro Bio pages.